B I09( —— )

Catalog No. M33303 CAS No. 1607803-67-7

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

B I09
Note

Research use only, not for human use.
Brief Description

B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.
Description

B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM.
In Vitro

B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM. Treatment of CLL cells with this inhibitor (B I09) mimick XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. B I09 is highly effective in inhibiting splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS stimulated B cells.
In Vivo

B I09 has a halflife of approximately 1.5 hours and reaches its peak concentration of approximately 39 μM in mouse plasma serum 15 minutes after administration. Administration of B I09 to CLL tumor-bearing mice suppress leukemic progression by inducing apoptosis and do not cause systemic toxicity.
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

IRE1
Research Area

——
Indication

——

1. Ranatunga S, et al. Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity. J Med Chem. 2014 May 22;57(10):4289-301.?

Calculator

molnova catalog